SEHK:2348Pharmaceuticals
Dawnrays Pharmaceutical (SEHK:2348) Margin Collapse To 17.4% Reinforces Bearish Profitability Narratives
Dawnrays Pharmaceutical (Holdings) (SEHK:2348) has reported FY 2025 first half revenue of C¥630.4 million and basic EPS of C¥0.070, with trailing 12 month revenue of C¥1.23 billion and EPS of C¥0.14 framing the recent run rate. The company has seen revenue move from C¥577.4 million in 1H 2024 to C¥630.4 million in 1H 2025, while basic EPS shifted from C¥0.329 to C¥0.070 over the same period. The latest print puts the spotlight firmly on how margins are holding up through this reset in...